

Alberico Del Torto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/35547/publications.pdf>

Version: 2024-02-01

135
papers

11,993
citations

36303

51
h-index

28297

105
g-index

138
all docs

138
docs citations

138
times ranked

7693
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study. <i>European Heart Journal Cardiovascular Imaging</i> , 2023, 24, 463-471.	1.2	7
2	Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. <i>Heart</i> , 2022, 108, 474-478.	2.9	8
3	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of "Evidence Base and Standardized Methods of Imaging". <i>Journal of Cardiac Failure</i> , 2022, 28, e1-e4.	1.7	8
4	Pearls from the First Gulf Cardiac Amyloidosis Summit 2021. <i>Emirates Medical Journal</i> , 2022, 3, 1-11.	0.3	0
5	Quantitative Myocardial Perfusion Predicts Outcomes in Patients With Prior Surgical Revascularization. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1141-1151.	2.8	10
6	Advances in Multimodality Cardiovascular Imaging in the Diagnosis of Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 758975.	2.4	8
7	RNA-targeting and gene editing therapies for transthyretin amyloidosis. <i>Nature Reviews Cardiology</i> , 2022, 19, 655-667.	13.7	64
8	Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1288-1303.	2.8	35
9	Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. <i>European Heart Journal</i> , 2022, 43, 2622-2632.	2.2	27
10	Society for Cardiovascular Magnetic Resonance (SCMR) guidelines for reporting cardiovascular magnetic resonance examinations. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2022, 24, 29.	3.3	13
11	Comparison of 99mTc-DPD Scintigraphy, CMR Imaging, and Echocardiography in Patients With V30M-Associated Hereditary Transthyretin Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2022, , .	5.3	0
12	Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2022, 24, 1700-1712.	7.1	26
13	Hemodialysis patients with less extracellular water overload and smaller cardiac atrial chamber sizes are at greater risk of a fall in blood pressure during dialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 16-23.	0.9	6
14	Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 189-199.	5.3	113
15	Quantitative cardiovascular magnetic resonance myocardial perfusion mapping to assess hyperaemic response to adenosine stress. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 273-281.	1.2	15
16	Cardiac output changes during exercise in heart failure patients: focus on mid-exercise. <i>ESC Heart Failure</i> , 2021, 8, 55-62.	3.1	6
17	T1 mapping and cardiac magnetic resonance feature tracking in mitral valve prolapse. <i>European Radiology</i> , 2021, 31, 1100-1109.	4.5	36
18	Visceral Adiposity Index (VAI) in Children and Adolescents with Obesity: No Association with Daily Energy Intake but Promising Tool to Identify Metabolic Syndrome (MetS). <i>Nutrients</i> , 2021, 13, 413.	4.1	31

#	ARTICLE	IF	CITATIONS
19	Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection. <i>EBioMedicine</i> , 2021, 65, 103259.	6.1	61
20	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. <i>European Heart Journal</i> , 2021, 42, 1554-1568.	2.2	434
21	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. <i>European Journal of Heart Failure</i> , 2021, 23, 512-526.	7.1	153
22	Cardiac Magnetic Resonance-Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, CIRCIMAGING121012506.	2.6	19
23	Prognostic Value of Pulmonary Transit Time and Pulmonary Blood Volume Estimation Using Myocardial Perfusion CMR. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2107-2119.	5.3	18
24	Prospective Case-Control Study of Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2155-2166.	5.3	111
25	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 493-502.	27.0	807
26	Demographic, multi-morbidity and genetic impact on myocardial involvement and its recovery from COVID-19: protocol design of COVID-HEART a UK, multicentre, observational study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 77.	3.3	14
27	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of Evidence Base and Standardized Methods of Imaging. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e000029.	2.6	48
28	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of Diagnostic Criteria and Appropriate Utilization. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e000030.	2.6	16
29	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of evidence base and standardized methods of imaging. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 1769-1774.	2.1	34
30	Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis. <i>Cardiology Clinics</i> , 2021, 39, 389-402.	2.2	7
31	Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin light chain (AL) amyloidosis. <i>British Journal of Haematology</i> , 2021, 194, 1016-1023.	2.5	3
32	Nutripedia: The Fight against the Fake News in Nutrition during Pregnancy and Early Life. <i>Nutrients</i> , 2021, 13, 2998.	4.1	9
33	Landmark Detection in Cardiac MRI by Using a Convolutional Neural Network. <i>Radiology: Artificial Intelligence</i> , 2021, 3, e200197.	5.8	24
34	Effect of remote ischaemic conditioning on infarct size and remodelling in ST-segment elevation myocardial infarction patients: the CONDI-2/ERIC-PPCI CMR substudy. <i>Basic Research in Cardiology</i> , 2021, 116, 59.	5.9	13
35	Reduced exercise capacity in patients with systemic sclerosis is associated with lower peak tissue oxygen extraction: a cardiovascular magnetic resonance-augmented cardiopulmonary exercise study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 118.	3.3	4
36	Cardiovascular Magnetic Resonance Parametric Mapping Techniques: Clinical Applications and Limitations. <i>Current Cardiology Reports</i> , 2021, 23, 185.	2.9	5

#	ARTICLE	IF	CITATIONS
37	SCMR level III/independent practitioner training guidelines for cardiovascular magnetic resonance: integration of a virtual training environment. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 139.	3.3	5
38	Cardiac Amyloidosis: A Review of Current Imaging Techniques. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 751293.	2.4	16
39	Anomalous origin of the left circumflex artery from the right coronary sinus with retro-aortic course: A potential malign variant. <i>Journal of Cardiovascular Computed Tomography</i> , 2020, 14, e54-e55.	1.3	3
40	Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 69-80.	5.3	125
41	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2 "Diagnostic criteria and appropriate utilization. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 659-673.	2.1	97
42	Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 909-920.	5.3	136
43	Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. <i>ESC Heart Failure</i> , 2020, 7, 3942-3949.	3.1	22
44	Sequential Strategy Including FFRCT Plus Stress-CTP Impacts on Management of Patients with Stable Chest Pain: The Stress-CTP RIPCORDER Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2147.	2.4	21
45	Society for Cardiovascular Magnetic Resonance (SCMR) guidance for re-activation of cardiovascular magnetic resonance practice after peak phase of the COVID-19 pandemic. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2020, 22, 58.	3.3	13
46	Automated Inline Analysis of Myocardial Perfusion MRI with Deep Learning. <i>Radiology: Artificial Intelligence</i> , 2020, 2, e200009.	5.8	32
47	Asymptomatic health-care worker screening during the COVID-19 pandemic " Authors' reply. <i>Lancet, The</i> , 2020, 396, 1394-1395.	13.7	7
48	Automated detection of left ventricle in arterial input function images for inline perfusion mapping using deep learning: A study of 15,000 patients. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 2788-2800.	3.0	19
49	Diffusion Tensor Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009901.	2.6	26
50	The value of screening biopsies in light chain (AL) and transthyretin (ATTR) amyloidosis. <i>European Journal of Haematology</i> , 2020, 105, 352-356.	2.2	10
51	Is Macronutrients Intake a Challenge for Cardiometabolic Risk in Obese Adolescents?. <i>Nutrients</i> , 2020, 12, 1785.	4.1	4
52	Diagnostic imaging of cardiac amyloidosis. <i>Nature Reviews Cardiology</i> , 2020, 17, 413-426.	13.7	84
53	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. <i>European Heart Journal</i> , 2020, 41, 1439-1447.	2.2	108
54	Assessment of Multivessel Coronary Artery Disease Using Cardiovascular Magnetic Resonance Pixelwise Quantitative Perfusion Mapping. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2546-2557.	5.3	30

#	ARTICLE	IF	CITATIONS
55	Role of CMR Mapping Techniques in Cardiac Hypertrophic Phenotype. <i>Diagnostics</i> , 2020, 10, 770.	2.6	19
56	Detailed Understating of Cardiac Amyloidosis by CMR. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1311-1313.	5.3	1
57	Atrial Involvement in Cardiac Amyloidosis. <i>JACC: CardioOncology</i> , 2020, 2, 732-734.	4.0	3
58	The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2020, 136, 40-40.	1.4	1
59	The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis. <i>Blood</i> , 2020, 136, 16-17.	1.4	2
60	Myocardial Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2345-2356.	5.3	74
61	Determinants of Rejection Rate for Coronary CT Angiography Fractional Flow Reserve Analysis. <i>Radiology</i> , 2019, 292, 597-605.	7.3	37
62	Intracardiac melanoma metastases on ¹⁸ F-FDG PET-CT—a case report and review of literature with imaging features. <i>BJR case Reports</i> , 2019, 5, 20180118.	0.2	0
63	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of “evidence base and standardized methods of imaging. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 2065-2123.	2.1	230
64	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. <i>Circulation: Heart Failure</i> , 2019, 12, e006075.	3.9	312
65	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of “Diagnostic Criteria and Appropriate Utilization. <i>Journal of Cardiac Failure</i> , 2019, 25, 854-865.	1.7	70
66	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of “Evidence Base and Standardized Methods of Imaging. <i>Journal of Cardiac Failure</i> , 2019, 25, e1-e39.	1.7	107
67	Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities. <i>Journal of the American Heart Association</i> , 2019, 8, e012097.	3.7	21
68	Interrogation of the infarcted and salvaged myocardium using multi-parametric mapping cardiovascular magnetic resonance in reperfused ST-segment elevation myocardial infarction patients. <i>Scientific Reports</i> , 2019, 9, 9056.	3.3	1
69	The UK National Amyloidosis Centre. <i>European Heart Journal</i> , 2019, 40, 1661-1664.	2.2	3
70	Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. <i>Circulation</i> , 2019, 140, 16-26.	1.6	288
71	Treatment of cardiac transthyretin amyloidosis: an update. <i>European Heart Journal</i> , 2019, 40, 3699-3706.	2.2	121
72	Dynamic Stress Computed Tomography Perfusion With a Whole-Heart Coverage Scanner in Addition to Coronary Computed Tomography Angiography and Fractional Flow Reserve Computed Tomography Derived. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2460-2471.	5.3	76

#	ARTICLE	IF	CITATIONS
73	Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. <i>Scientific Reports</i> , 2019, 9, 1388.	3.3	27
74	Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMR to Detect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1958-1969.	5.3	140
75	A case report of eosinophilic granulomatosis and polyangiitis myocarditis presenting as ST elevation myocardial infarction and showing positive response to immunotherapy. <i>European Heart Journal - Case Reports</i> , 2019, 3, 1-6.	0.6	3
76	A workflow for patient-specific fluid-structure interaction analysis of the mitral valve: A proof of concept on a mitral regurgitation case. <i>Medical Engineering and Physics</i> , 2019, 74, 153-161.	1.7	13
77	Relative Left Ventricular Apical Sparing of Longitudinal Strain in Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1174-1176.	5.3	23
78	Analysis of the <i>TTR</i> gene in the investigation of amyloidosis: A 25-year single UK center experience. <i>Human Mutation</i> , 2019, 40, 90-96.	2.5	29
79	Do Pre-Hemodialysis Estimates of Extracellular Volume Excess Using Bioimpedance and N-Terminal Brain Natriuretic Peptide Correlate With Cardiac Chamber Size Measured by Magnetic Resonance Imaging?. <i>Therapeutic Apheresis and Dialysis</i> , 2019, 23, 362-368.	0.9	9
80	Native T1 and Extracellular Volume in Transthyretin Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 810-819.	5.3	172
81	Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 823-833.	5.3	113
82	Myocardial native T1 and extracellular volume with healthy ageing and gender. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 615-621.	1.2	78
83	Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	94
84	Cardiac amyloidosis. <i>Clinical Medicine</i> , 2018, 18, s30-s35.	1.9	135
85	A new staging system for cardiac transthyretin amyloidosis. <i>European Heart Journal</i> , 2018, 39, 2799-2806.	2.2	396
86	Extracellular volume with bolus-only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1677-1684.	3.4	7
87	Diagnostic accuracy of simultaneous evaluation of coronary arteries and myocardial perfusion with single stress cardiac computed tomography acquisition compared to invasive coronary angiography plus invasive fractional flow reserve. <i>International Journal of Cardiology</i> , 2018, 273, 263-268.	1.7	22
88	Therapies for cardiac light chain amyloidosis: An update. <i>International Journal of Cardiology</i> , 2018, 271, 152-160.	1.7	31
89	Myocardial Edema and Prognosis in Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2919-2931.	2.8	145
90	High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. <i>Sleep Medicine</i> , 2017, 32, 191-197.	1.6	5

#	ARTICLE	IF	CITATIONS
91	Diagnostic performance of T_1 and T_2 mapping to detect intramyocardial hemorrhage in reperfused ST-segment elevation myocardial infarction (STEMI) patients. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 877-886.	3.4	24
92	Automatic quantification of the myocardial extracellular volume by cardiac computed tomography: Synthetic ECV by CCT. <i>Journal of Cardiovascular Computed Tomography</i> , 2017, 11, 221-226.	1.3	34
93	A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 72-73.	3.0	3
94	Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. <i>European Heart Journal</i> , 2017, 38, 1905-1908.	2.2	144
95	Prognostic utility of the Perugini grading of ^{99m}Tc -DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1344-1350.	1.2	124
96	Lvad pump speed increase is associated with increased peak exercise cardiac output and VO_2 , postponed anaerobic threshold and improved ventilatory efficiency. <i>International Journal of Cardiology</i> , 2017, 230, 28-32.	1.7	39
97	Contribution of central and peripheral factors at peak exercise in heart failure patients with progressive severity of exercise limitation. <i>International Journal of Cardiology</i> , 2017, 248, 252-256.	1.7	20
98	Magnetic Resonance in Transthyretin Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 466-477.	2.8	290
99	Full left ventricular coverage is essential for the accurate quantification of the area-at-risk by T_1 and T_2 mapping. <i>Scientific Reports</i> , 2017, 7, 4871.	3.3	6
100	Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 162-166.	3.0	61
101	A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid. <i>BMC Medical Imaging</i> , 2017, 17, 3.	2.7	9
102	Insight into hypertrophied hearts: a cardiovascular magnetic resonance study of papillary muscle mass and T_1 mapping. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1034-1040.	1.2	31
103	Cardiac computed tomography for the detection of cardiac amyloidosis. <i>Journal of Cardiovascular Computed Tomography</i> , 2017, 11, 155-156.	1.3	3
104	Impact of microvascular obstruction on semiautomated techniques for quantifying acute and chronic myocardial infarction by cardiovascular magnetic resonance. <i>Open Heart</i> , 2016, 3, e000535.	2.3	18
105	Residual Myocardial Iron Following Intramyocardial Hemorrhage During the Convalescent Phase of Reperfused ST-Segment Elevation Myocardial Infarction and Adverse Left Ventricular Remodeling. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	2.6	120
106	Response to Letters Regarding Article, "Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis". <i>Circulation</i> , 2016, 133, e450-1.	1.6	4
107	Prognosis in Cardiac Amyloidosis by LGE. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 687-689.	5.3	4
108	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. <i>Circulation</i> , 2016, 133, 2404-2412.	1.6	1,335

#	ARTICLE	IF	CITATIONS
109	Staging Cardiac Amyloidosis With CMR. JACC: Cardiovascular Imaging, 2016, 9, 1278-1279.	5.3	10
110	Ultrafast Magnetic Resonance Imaging for Iron Quantification in Thalassemia Participants in the Developing World. Circulation, 2016, 134, 432-434.	1.6	23
111	Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	210
112	Automated Extracellular Volume Fraction Mapping Provides Insights Into the Pathophysiology of Left Ventricular Remodeling Post-“Reperfused ST-Elevation Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	3.7	46
113	Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis. Nephrology Dialysis Transplantation, 2016, 33, gfw375.	0.7	18
114	Automatic Measurement of the Myocardial Interstitium. JACC: Cardiovascular Imaging, 2016, 9, 54-63.	5.3	127
115	Defining left ventricular remodeling following acute ST-segment elevation myocardial infarction using cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 26.	3.3	55
116	Dark blood late enhancement imaging. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 77.	3.3	64
117	Quantification of both the area-at-risk and acute myocardial infarct size in ST-segment elevation myocardial infarction using T1-mapping. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 57.	3.3	41
118	Prospective comparison of novel dark blood late gadolinium enhancement with conventional bright blood imaging for the detection of scar. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 91.	3.3	36
119	Acute Increase of Cardiac Output Reduces Central Sleep Apneas in Heart Failure Patients. Journal of the American College of Cardiology, 2015, 66, 2571-2572.	2.8	13
120	T1 mapping and T2 mapping at 3T for quantifying the area-at-risk in reperfused STEMI patients. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 73.	3.3	70
121	Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2015, 16, 681.	1.5	61
122	Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. Journal of Cardiovascular Computed Tomography, 2015, 9, 585-592.	1.3	108
123	T1 mapping and survival in systemic light-chain amyloidosis. European Heart Journal, 2015, 36, 244-251.	2.2	310
124	A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. European Heart Journal, 2015, 36, 1098-1105.	2.2	129
125	Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Radiology, 2015, 277, 388-397.	7.3	146
126	Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. Lancet Haematology, the, 2015, 2, e241-e250.	4.6	105

#	ARTICLE	IF	CITATIONS
127	Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. <i>Circulation</i> , 2015, 132, 1570-1579.	1.6	442
128	Remote Ischemic Conditioning Reduces Myocardial Infarct Size and Edema in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 178-188.	2.9	199
129	Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2014, 16, 99.	3.3	154
130	Native T1 Mapping in Transthyretin Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 157-165.	5.3	339
131	Incremental Prognostic Value of Myocardial Fibrosis in Patients With Non-Ischemic Cardiomyopathy Without Congestive Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 448-456.	3.9	94
132	T1 Mapping for Characterization of Intracellular and Extracellular Myocardial Diseases in Heart Failure. <i>Current Cardiovascular Imaging Reports</i> , 2014, 7, 9287.	0.6	37
133	Noncontrast T1 Mapping for the Diagnosis of Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 488-497.	5.3	517
134	Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 392-398.	2.6	399
135	Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2012, 14, 87.	3.3	207